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~ Lipid Levels, Adherence to Medlcltlon, Ba~llno 
Chma~erlatics In the Cholesterol and RKur~ent 
Evtmts (CARE) Study 
J ,MO, Am~l ,  BR O~v=~, DT, Nard, W- InPut, d~, S Lewd, RM K~hn, 
SP- Gl~_s~, KM 0¢~w, B, Kimmct, F,M, ~¢k~ LH~-C, LOn~, ON. 
~ k ~  ~ Uti,~ati¢~ ot ~ ~l(~ln¢~¢P,~O tO lilL~! ~we~¢qng treatment fem~!n 
k~v in th# cg~.~m~ty. In ~f f~st ,  in the_ l~ l  y~af Of Io!~w=L~ of 41~,9 
pat~nt~ in CARI~, the ¢(~tm~t~gn Fdte to{ t~nt~l s_t~t me.L/~tion w~, ~6% 
in p!~_abO (pL_) ~ln~l {]4% in the ~gf~v~t~tin (PRA) g to~ ar~l the~=~ I ti~nt~ 
R~,~P~-- In I t~  pattCrtts wit~ an MI ~ "ave3~g~" CbetOSter01 k~vels, 
PRA eL~l~,3Nly riL~d~¢e~ Li~=. cho~_~terol We_is ~ the pnmal~ enq~ird, 
ratA! O0,t'~m~P/W~I Or ~, f~ta l  MI, by 24% TLe#iment L_DL levels were 
tit~ was - 41 mahdi in tl'~_ PRA _~rctJ~ ~ 2 n~Jd! in tho IPL ~m~.  The5 
LDL Ch~ w~S !m~ady ¢ofle__lat _ed with ~it~rence in the PRA grc=up (p 
0.0001) reP{e.,c,~nting # 0,.5 m~dt c~_ reas~ in LDL f0r each t% in, Czease in 
ac~rEm~e. A(~ml~e w"d,~  5am~ in each treatment gre~ and remained 
s t~e over the m~J~n ~Ik~ ~p of 5 yem~, U~ng a 5tepwise regressmn 
ra,~je!, befter adherence to sLudy m¢-d~atm, n was related to race (white) p 
* OOQOt, not being a cuneof s m.aker p < 0.0001, sex (female) p - 003, 
and rot being empleyecl p < 004 Ce~n baseline ¢l~ractensr~cs including 
education, cat ty  with d~al~!~.~ Of hype~tensma, and bO(~y mass index 
did not cometate sicjnifican~ with edt'~, rence. 
Conclusions: Thus, PRA was well t~eraled in CARE. ac~nerance to as- 
signed trealment remmnecl h~gh dunng active pat]ant follow-up in th~s clinical 
mat, and adherence was correlated with improved reduclmns in ~L  lev- 
els A~rence  lo treatment was related most strongly to racu and srn~lung 
status 
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• As~iated Risk Factors do Not Prevent the 
Beneficial Effect of Aggressive Cholesterol 
Lowering: Post CABG Trial 
L. Campeau, G. Knatteeud, D. Hunmnghake, M. Domanstu, C. White, 
J. Canner, J. Fonester, N. Geller, F Gobel, JA.  Herd, B. Heogwerf, 
Y. Rosenberg. Montreal Hear Instffute. Montreal, Quebec. Canada 
Background: The Post CABG trial (N Engl J Mad 1997; 336: 153-162) 
showed in 1351 patients that an aggressive LDL-cholesteml lowering (AL) 
to 93-97 mcj/dl dunng 4.3 years parted compared to a mederate Iowenng 
(ML) to 132-136 mg~dl significantly delayed progression of atheresclero~is 
(lumen reduction ",0.6 nun) in saphenous vein grafts placed t to I1 years 
previously (27% vs 39%: p < 0.001). 
Methods: Using a graft-based analysis (generalized estimating equabon 
model), the probabilities of progression (Prog) were obteinud for both groups, 
AL and ML  The following risk factors (RF) were considered: smoking, alia- 
bales mellitus, hypertension, HDL-cholesterol ,:40 mcj/dl, thglycendes < 145 
mg/dl, and the number o! RF. 
Results: The same beneficial effect is observed as judged by a similar 
significant nsk ratio (0.5 to 0.6), and no interaction between subeategones 
of RF. Detailed analyses of the number of nsk factors are shown in the table 
below. 
NO RF Preg. t%) P value RR (95== CI) 
AL ML 
0-1 274 32 5 0 12 0.78 (058-1 06) 
2 263 43,6 .0,0001 8.46 (032-0,66) 
-3 29.8 46.6 00001 0.49 (0 34-070) 
Conclusion: LDL-cholesterol lowering to 95 mg/dl compared to 135 mgJdl 
delayed saphenous vein graft atheroscleresis to the same degree in palrents 
with or without associated risk factors. 
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~5-]  Does the Presence of Certain Cardiac Risk  Factors  
Posi t ive ly  In f luence  R isk  Factor  In tervent ions?  
S. Mora, RS. Stafford, R.E. Chaput, T. Bishop, R.C Pastemak. 
Massachusetts General Hospital Boston, MA, USA 
Screening and treatment of cardiac risk factors (RF) by physicians remains 
suboptimal. We explored the association between RF intervention and pa- 
tient (pt) characteristics to identify predictors of risk factor interventions. A 
cross-sectional survey of 234 outpatients in a cardiology practice over 6 
m~eths ( t~ ~7l w~, un~rb~kcn PtS chn~C~! ¢.¢r~t~o~ nay factors ~r~ 
~ntorvcntL~rLs ~.Ao~rr~l (;t~nn 0 the vi~t~, wcr¢ ~tr(~(,lecl tror~ fits fT~!  
racer0, Pot~n~l Confoge(~:~cr,~ wig.f0 co~tfotle0 t~r uSm 0 Io~s~ r i~S~0n 
tO ~terr~ne the mdepef~_:nt !~k¢flh0,0~ of n~k f~_¢tCf mtr;rvent~o,"~ ~tend, 
vt_~,U'_¢31 ¥isJts Of ~3,4 ~t W~.|Ls, I~lO0~ pre~ut~ (0P) ~¢mef f f  W_~ r@ 
• ¢t i~s_s_e.~_~m~_nt~ i  43%,, ~P,(I ~t  ¢O~ft~JiP, 0 in -24%, PI~= with-h~ cr~l 
testin 9 (OR 110, 4,~--~,~), ~e.t ae~¢nf~ (OR 3,6, 10=7-2) ~ ~e_t 
b~t not OP ot Chef m~iur¢t,~__ntP, O i~ l~ I~s w#r~ Oflly mo~'e likely In 
havo deer a s_scspm~fits (OR ~,9, 1 r~,5)  , Hyp#rten~w¢ ~ r~etv~l I¢~,~ 
dt¢! counseling (OR 0.37, O-2--0 9) Ago and sex h~d no efl_e¢_t On in~rveno 
ti0ns 
Co~/ t~on Physicians more ag~l~ess~vely intcn/en~d with t~--¢ and 
hyp~rchol _e.~,tcr¢m~¢ pt_s ¢orr~,~fe~ |O hylL~itenSlv@ Of ~,Td~r=t~c. el.s, Ri~k fa_ctor 
¢0nft0| may be_ lm~mved bY recognizing thC=l Certain P~_setiP~ e~k fac l~ 
barn~r~ to lnt¢~¢ntion 
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E.ect ot p!a...om=y=t(e)l.e L l= o .  
Cardiov_ascu!ar Outcomes A~r PTCA or CABG In 
EAST 
X-Q. Zha.o, AS. Kosm~ki, MR Malffmw, HX Bamhaft, J.W D~vis, 
BG. Brown. S-B. King, I Un~v o! Washington. _Seattle. WA an¢l Ernoq/ 
Urw.. At/anta, GA. USA 
Background:The p f~_~ic  value of hemocyst(e)ine (H (e)) levels in coronary 
artery dJs~a3e (CAD) patients (pts) receiving PTCA or CABG was exan~necJ 
in the Emo~ Ang~opfasty vs  Surgery Thai (EAST). 
Me~:  Of 392 m~ltlvassel d~sease pts who were randomized to an initia! 
strategy of PTCA or CABG, 295 had at least one H(e~ level measured dunng 
the first 3 yre (~t he study. The mean H(e) level was 12.8 ± 5.2 .molJL and 
was not different between PTCA and CABG pts, The pts were followed for 
any adverse can~ovasCUlar outcomes (ACVO) including death, myocardial 
infarction (MI), stroke and addibonal revasculanzation procedure(s) (PTCA 
or CABG) (AddPro) for 5 yrs after the initial PTCA or CABG. e l  295 pts, 27 
died. 55 sulferc--cl non-fatal ML 18 had stroke and 114 expanenced AdclPre. 
The mean H(e) level was compared between pts with and without ACVO, 
and the % of pls with ACVO wthin 5 yrs was computed for each H(e) quadile 
(Q) The QI is H(e) <9 7, the Q2 is ~_9.7 and ~ 117, the Q3 =s ~117 and 
14.7, and the Q4 is : 14 7 i,mol/L, respectively, 
Results. 
H(e) and adverse ca)'d~ovascutar ouTo3rnes 
Mean H(e)'i, moEL % 0tp~ m 
Q! Q2 Q3 Q4 
Deah .35 T 7 15 30 4B t 
MI'" *0 3 25 29 24 22 
Stmke 09 22 33 33 12 
AddPro 02 26 26 24 24 
• the dttference ~n H(e) betv~een pts wiIrl and ~,~IhQut the adverse cardiovascular md- 
cl3mes: r: p . oool: ~; p 001; "" nGn-iafalMI 
Concluszons: In EAST. Hie) levels are a strong and graded predictor 
of modality in CAD pte following PTCA or CABG. However. H(e) levels 
did not predict future non-iatal myocardial infarction, stroke or adcStionnl 
revasculanzalion procedure(s) after initial PTCA or CABG Clinical trials wLth 
H(e)-Iowering therapy appear to be indicated, 
Autonomic/Hormonal Modulation of 
Arrhythmias 
Monday, March 30, 1998, 4:00 p.m.-5:30 p.m. 
Georgia World Congress Center. Room 257W 
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F~-~ Cerebral Vasoconstriction Occurs Prior to Systemic 
Vasodilatation in Neurocardiogenic Syncope 
D. Dan. J.B. Hoag, K.A. Ellenbogen, D.L Eckberg. D.M Gilh,.jan. Medical 
College of Virginia and McGuire VA Medical Center. Richmond. VA. USA 
Cerebral blood flow (CBF) may be affected in patients with neurecardio- 
genie syncope due to an abnormal neural reflex. We hypothesized that 
cerebral hemodynamics change independently from systemic vasoddata- 
tion. The mean ar?en~ pressure (MAP with Finapr'csl and CBF velOCities 
